Drug Trial Radar · NCT02213289
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jan 20, 2015
Primary completion
Feb 1, 2020
Study completion Aug 20, 2020
Sponsor
- Lead sponsor
- University of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AbbVie
- First posted
- Aug 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
Conditions
- Adenocarcinoma
Interventions
TrastuzumabDrug
Trastuzumab
ABT-806Drug
ABT-806
BemarituzumabDrug
Bemarituzumab
RamucirumabDrug
Ramucirumab
NivolumabDrug
Nivolumab
Standard cytotherapyDrug
FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Up to 60 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.